
AbbVie's Migraine Drug Outperforms Generic Treatment In Head-To-Head Trial
AbbVie Inc ABBV on Wednesday released topline results from its Phase 3 TEMPLE study evaluating the tolerability, safety, and efficacy of atogepant (QULIPTA/AQUIPTA, 60 mg once daily) compared to the highest tolerated dose of topiramate (50, 75 or 100 …